DSIP (delta sleep-inducing peptide) regulatory status
Current status of DSIP (delta sleep-inducing peptide) in the United States: Nomination withdrawn. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of DSIP (delta sleep-inducing peptide)?
- FDA and compounding
- Not an FDA approved drug. FDA previously placed emideltide (DSIP) in 503A Category 2 and now lists it among bulk drug substances nominated but withdrawn, so it is in no 503A category and outside FDA's interim enforcement policy. FDA nonetheless presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026 and proposed that it not be included on the 503A bulks list. FDA had not posted minutes or a vote result as of the last verification date, and no proposed or final rule has been published. It is not on the 503A bulks list, so compounding pharmacies have no federal basis to compound it, and no 503B pathway has been identified.
- WADA
- WADA prohibited
- Access path
- Not available as an FDA approved product.
- Not on the 503A bulks list: FDA's own July 2026 briefing recommended against listing it, and FDA has not posted the committee's vote.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Full DSIP (delta sleep-inducing peptide) page: evidence, dosing in the literature, and sources
How has the status of DSIP (delta sleep-inducing peptide) changed over time?
- PCAC
FDA advisory committee reviews DSIP; FDA's briefing recommends against listing
At the July 24, 2026 meeting, FDA presented delta sleep-inducing peptide (DSIP, emideltide) to its Pharmacy Compounding Advisory Committee and proposed not adding it to the 503A bulks list, citing poor characterization, insufficient safety data, immunogenicity concerns, and lack of evidence of effectiveness. FDA has not posted the vote or minutes. Its nomination was withdrawn, so it remains outside FDA's interim policy.
Regulatory: Nomination withdrawnSource: FDA: Pharmacy Compounding Advisory Committee, July 24, 2026, FDA presentation slides - FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for DSIP (delta sleep-inducing peptide) and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [5]FDA: Pharmacy Compounding Advisory Committee, July 24, 2026, FDA presentation slidesFDA, 2026
- [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026